FDA
-
-
-
-
-
-
-
Vir Biotechnology Announces AASLD The Liver MeetingĀ® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High R
-
-
-
-
-
-
-
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
-
-
-
-
-
-
-
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
-
-
-
-
-
-
-
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
-
-
-
-
-
-
-
Vir Biotechnology Provides Corporate Update and ReportsĀ First Quarter 2022 Financial Results
-
-
-
-
-
-
-
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
-
323,325 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

